Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB).

导出 LinkOut

翻译打印收藏纠错

作者： Vikas,Ostwal ^[1] ; Sarika,Mandavkar ^[1] ; Prabhat,Bhargava ^[1] ; Sujay,Srinivas ^[1] ; Akhil,Kapoor ^[2] ; Omshree,Shetty ^[3] ; Sadhana,Kannan ^[4] ; Deepali,Chaugule ^[1] ; Rajshree,Patil ^[1] ; Manali,Parulekar ^[1] ; Chaitali,Nashikkar ^[5] ; Suman Kumar,Ankathi ^[6] ; Akshay Dwarka,Baheti ^[6] ; Daksha,Mehta ^[6] ; Rajiv Kumar,Kaushal ^[7] ; Subhash,Yadav ^[7] ; Aekta,Shah ^[7] ; Shraddha,Patkar ^[8] ; Mahesh,Goel ^[8] ; Anant,Ramaswamy ^[9]

作者单位： Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India. ^[1] Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India. ^[2] Department of Molecular Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India. ^[3] Department of Statistics, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute (HBNI), Mumbai, India. ^[4] Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India. ^[5] Department of Radiology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India. ^[6] Department of Pathology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India. ^[7] Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India. ^[8] Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India. ^[9]